Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Bookman

Showing results (41-50 of 102) with videos related to

Pageof 11
Sort By:
Gynecologic Oncology|October 29, 2011
Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group studyBunja Rungruang, Austin Miller, Scott D Richard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182Neil S Horowitz, Austin Miller, Bunja Rungruang, et al.
Gynecologic Oncology|June 25, 2013
Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182Noah Rodriguez, Austin Miller, Scott D Richard, et al.
Medical Care|July 31, 2008
Selecting high priority quality measures for breast cancer quality improvementMichael J Hassett, Melissa E Hughes, Joyce C Niland, et al.
Gynecologic Oncology|December 17, 2013
The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group studyAmanda Nickles Fader, James Java, Thomas C Krivak, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2008
Factors associated with guideline-concordant use of radiotherapy after mastectomy in the national comprehensive cancer networkRinaa S Punglia, Melissa E Hughes, Stephen B Edge, et al.
Gynecologic Oncology|July 4, 2008
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology GroupMark A Morgan, Kathleen M Darcy, Peter G Rose, et al.
Journal of the National Cancer Institute|March 15, 2014
Better therapeutic trials in ovarian cancerMichael A Bookman, C Blake Gilks, Elise C Kohn, et al.
Gynecologic Oncology|November 25, 2011
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group studyChunqiao Tian, Christine B Ambrosone, Kathleen M Darcy, et al.
Gynecologic Oncology|January 21, 2012
Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group studyJennifer M Rubatt, Kathleen M Darcy, Chunqiao Tian, et al.
Pageof 11

Showing results (41-50 of 102) with videos related to

Sort By:
Pageof 11
Gynecologic Oncology|October 29, 2011
Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group studyBunja Rungruang, Austin Miller, Scott D Richard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182Neil S Horowitz, Austin Miller, Bunja Rungruang, et al.
Gynecologic Oncology|June 25, 2013
Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182Noah Rodriguez, Austin Miller, Scott D Richard, et al.
Medical Care|July 31, 2008
Selecting high priority quality measures for breast cancer quality improvementMichael J Hassett, Melissa E Hughes, Joyce C Niland, et al.
Gynecologic Oncology|December 17, 2013
The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group studyAmanda Nickles Fader, James Java, Thomas C Krivak, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2008
Factors associated with guideline-concordant use of radiotherapy after mastectomy in the national comprehensive cancer networkRinaa S Punglia, Melissa E Hughes, Stephen B Edge, et al.
Gynecologic Oncology|July 4, 2008
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology GroupMark A Morgan, Kathleen M Darcy, Peter G Rose, et al.
Journal of the National Cancer Institute|March 15, 2014
Better therapeutic trials in ovarian cancerMichael A Bookman, C Blake Gilks, Elise C Kohn, et al.
Gynecologic Oncology|November 25, 2011
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group studyChunqiao Tian, Christine B Ambrosone, Kathleen M Darcy, et al.
Gynecologic Oncology|January 21, 2012
Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group studyJennifer M Rubatt, Kathleen M Darcy, Chunqiao Tian, et al.
Pageof 11